SOX2 and neoplasm: The PRMT1 inhibitor DCLX069 in DNM can be rapidly released in response to elevated intracellular GSH levels, leading to the disruption of the PRMT1-SOX2 pathway that reduces tumor cell stemness and enhances chemosensitivity.